Centessa stock falls as company pulls plug on lixivaptan kidney disease program
seekingalpha.com
finance
2022-06-02 11:54:49

gorodenkoff/iStock via Getty Images Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both a phase 3 trial called ACTION and an open-label study, dubbed ALERT. ADPKD is a genetic disorder characterized by growth of cysts in the kidneys. The company said elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were recently seen in one patients in the ALERT study.
